These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12629578)

  • 1. Attention-deficit/hyperactivity disorder: current aspects on pharmacogenetics.
    Rohde LA; Roman T; Hutz MH
    Pharmacogenomics J; 2003; 3(1):11-3. PubMed ID: 12629578
    [No Abstract]   [Full Text] [Related]  

  • 2. Attention deficit and hyperactivity disorder: review of genetic association studies.
    Galili-Weisstub E; Segman RH
    Isr J Psychiatry Relat Sci; 2003; 40(1):57-66. PubMed ID: 12817670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the biological bases of ADHD: what have we learned from imaging studies?
    Durston S
    Ment Retard Dev Disabil Res Rev; 2003; 9(3):184-95. PubMed ID: 12953298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hereditary basis of attention deficit and hyperactivity disorder].
    Manor I; Ebstein R
    Harefuah; 2000 Nov; 139(9-10):382-5. PubMed ID: 11341221
    [No Abstract]   [Full Text] [Related]  

  • 5. The early development of child psychopharmacogenetics.
    Cook EH
    J Am Acad Child Adolesc Psychiatry; 1999 Dec; 38(12):1478-81. PubMed ID: 10596246
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study.
    Rohde LA; Roman T; Szobot C; Cunha RD; Hutz MH; Biederman J
    Synapse; 2003 May; 48(2):87-9. PubMed ID: 12619042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
    Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
    Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What do dopamine transporter and catechol-o-methyltransferase tell us about attention deficit-hyperactivity disorder? Pharmacogenomic implications.
    Levy F
    Aust N Z J Psychiatry; 2007 Jan; 41(1):10-6. PubMed ID: 17464676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the risk allele of dopamine transporter gene (DAT1*10) in Omani male children with attention-deficit hyperactivity disorder.
    Simsek M; Al-Sharbati M; Al-Adawi S; Ganguly SS; Lawatia K
    Clin Biochem; 2005 Aug; 38(8):739-42. PubMed ID: 15993876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics of adult attention-deficit/hyperactivity disorder.
    Faraone SV
    Psychiatr Clin North Am; 2004 Jun; 27(2):303-21. PubMed ID: 15063999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetics of attention-deficit/hyperactivity disorder.
    Faraone SV; Perlis RH; Doyle AE; Smoller JW; Goralnick JJ; Holmgren MA; Sklar P
    Biol Psychiatry; 2005 Jun; 57(11):1313-23. PubMed ID: 15950004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles.
    Oades RD; Sadile AG; Sagvolden T; Viggiano D; Zuddas A; Devoto P; Aase H; Johansen EB; Ruocco LA; Russell VA
    Dev Sci; 2005 Mar; 8(2):122-31. PubMed ID: 15720370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence and function in pharmacogenomics.
    Licinio J; Wong ML
    Pharmacogenomics J; 2003; 3(3):123. PubMed ID: 12815360
    [No Abstract]   [Full Text] [Related]  

  • 15. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate.
    Krause KH; Dresel S; Krause J; Kung HF; Tatsch K; Lochmüller H
    J Neurol; 2002 Aug; 249(8):1116-8. PubMed ID: 12420715
    [No Abstract]   [Full Text] [Related]  

  • 16. PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.
    Stevens T; Sangkuhl K; Brown JT; Altman RB; Klein TE
    Pharmacogenet Genomics; 2019 Aug; 29(6):136-154. PubMed ID: 30950912
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine transporter genotype influences the physiological response to medication in ADHD.
    Gilbert DL; Wang Z; Sallee FR; Ridel KR; Merhar S; Zhang J; Lipps TD; White C; Badreldin N; Wassermann EM
    Brain; 2006 Aug; 129(Pt 8):2038-46. PubMed ID: 16760197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attention-deficit/hyperactivity disorder pharmacogenomics.
    McGough JJ
    Biol Psychiatry; 2005 Jun; 57(11):1367-73. PubMed ID: 15950009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention deficit hyperactivity disorder pharmacogenetics: the dopamine transporter and D4 receptor.
    McGough JJ
    Pharmacogenomics; 2012 Mar; 13(4):365-8. PubMed ID: 22379991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.